Navigation Links
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
Date:3/12/2009

City. Dr. McNally presented a corporate overview of GeoVax and its DNA/MVA vaccine technology, showcasing the scientific rationale and encouraging data from the Company's completed studies and trials. GeoVax's presentation was offered via a live webcast. A replay of the webcast is available on the Company's website until April 10. Operational Highlights for Calendar Year 2008 Clinical Progress * In October 2008, GeoVax presented data on its Phase 1 AIDS vaccine trial (HVTN 065) at the AIDS Vaccine 2008 conference, in Cape Town, South Africa. The presentation, entitled "Two HIV DNA Primes Maximize T Cell Responses Induced by the GeoVax DNA/MVA Vaccine Regimen Administered to Healthy Seronegative Adults (HVTN 065)," was given by Dr. Paul A. Goepfert, M.D., Associate Professor, Division of Infectious Diseases, Department of Medicine, University of Alabama. Dr. Goepfert is the HVTN 065 Protocol Team chair. The trial results reveal the GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate anti-HIV/AIDS immune responses) at both low (1/10th) dose and full doses. Other highlights of the presentation included: O GeoVax vaccines were well tolerated with no or mild local and systemic reactions in the majority of trial participants. O Eighty percent of both the low and full dose trial participants responded to the vaccine which stimulated anti- HIV T-cell (white blood cell) and antibody responses. O More volunteers had antibody responses to the full dose than to the 1/10th dose vaccine, whereas response rates for T cells were similar for the 1/10th and full dose. O Two DNA primes were more effective than one DNA prime or no DNA primes at el
'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
2. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
3. GeoVax to Present at the BIO CEO & Investor Conference 2009
4. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
5. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
8. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
9. GeoVax Further Strengthens Management Team
10. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
11. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Franciscan ... use of capnography for respiratory monitoring outside ... of healthcare leaders in embracing state-of-the-art patient ... effectively patients are breathing and can alert ... By measuring the amount of carbon dioxide ...
(Date:7/10/2014)... 2014   Ceres, Inc . (Nasdaq: ... today financial results for the three months ended May ... Ceres reported that the company and its ... growing season in Brazil, which concluded in June, despite ... evaluation areas for part of the growing season. Yields ...
(Date:7/10/2014)... Understanding the basis of psychiatric disorders has been extremely ... increase risk but are insufficient to cause disease. Now ... Cell Press journal Cell Stem Cell describe ... genetic risks interact with other risk factors or environmental ... Their research pinpoints a genetic variant that may predispose ...
(Date:7/10/2014)... the University of Illinois at Urbana-Champaign provides new ... of spin and heat at the nanoscale, and ... for data storage and information processing. , ... momentum. In a typical charge current, electrons, spin-angular-momentum ... explained David Cahill, a professor of materials science ...
Breaking Biology Technology:Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2University of Illinois study advances limits for ultrafast nano-devices 2
... 30 , - 76% Higher ... Control Versus Lantus(R) , Sanofi-aventis (EURONEXT: ... a,head-to-head study providing further evidence on the efficacy of once-daily,24-hour ... detemir. The study was presented during the 45th,Annual Meeting of ...
... Dr. John McPherson, Platform Leader, Cancer Genomics and High-Throughput ... Ontario Institute for Cancer Research (OICR) led a team ... the NEBNext(TM) DNA Sample Prep Reagents for use with ... the evaluation, "We are constantly striving for the best ...
... physicists have created the first atomic-scale maps of ... of producing "designer dots" that can be tailored ... atoms or nanoparticles---are tiny semiconductor crystals with wide-ranging ... and other technologies. Each dot is a well-ordered ...
Cached Biology Technology:Superior Efficacy-dose Ratio for Lantus(R) Over detemir 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 3Superior Efficacy-dose Ratio for Lantus(R) Over detemir 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 5Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing 2U-M physicists create first atomic-scale map of quantum dots 2
(Date:7/11/2014)... 11, 2014 Research and Markets ... Technology Market - Industry Analysis Size Share Growth Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... created a need for high level security in both ... authentication such as username and passwords, tokens etc. are ...
(Date:7/10/2014)... other major cities in New Mexico, nearly every public ... rather than precious potable water supplies. Across the U.S. ... golf courses receive treated effluent. Reusing the effluent increases ... courses and homeowners alike fertilize their lawns during the ... A New Mexico State University turfgrass expert has a ...
(Date:7/10/2014)...  Aware, Inc. (NASDAQ: AWRE ), a ... on June 26, 2014 that its Board of Directors ... share, or approximately $40 million in total.  The Board ... a payment date of July 24, 2014.  The Company ... an ex-dividend date for this special cash dividend.  An ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2'Tailored' water -- the latest in lawn care 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... Clinic,s Genomic Medicine Institute have revealed multiple genetic discoveries that ... patients who are predisposed to breast and kidney cancer. ... cancerous tumors, is published in the Dec. 22 issue of ... JAMA ). Charis Eng, M.D., Ph.D, Chair of ...
... The leading causes of death have shifted from infectious diseases ... illnesses may be affected by diet. In a study published ... the American Dietetic Association , researchers investigated empirical data regarding ... the eating patterns of over 2500 adults between the ages ...
... , ARLINGTON, Va. Dubbed the "Brilliant 10" by ... 2010 list of top young scientists have received funding ... two ONR-funded researchers are Dr. Chiara Daraio, a 2010 ... and designed a nonlinear acoustic lens, which has the ...
Cached Biology News:Researchers discover genetic predisposition for breast, kidney cancers 2Eating healthier means living longer 2ONR-funded researchers among Popular Science magazine's 'Brilliant 10' 2